Lupin announced on Thursday that it has secured approval from the US Food and Drug Administration (USFDA) to market generic versions of diabetes treatment drugs.

The company received clearance for its abbreviated new drug applications (ANDAs) for Liraglutide Injection in single-patient-use prefilled pens and Glucagon for Injection vials, according to an official statement.

Both products will be manufactured at Lupin’s injectable manufacturing facility located in Nagpur, the company added.